OPTR SEC备案 - Optimer Pharmaceuticals Inc- 年度报告、委托书、招股说明书

基本统计

CIK

1142576

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Optimer Pharmaceuticals Inc

SEC Filings (Chronological Order)

本页提供了美国证券交易委员会（SEC）备案的完整、按时间顺序排列的列表，不包括我们在其他地方提供的所有权备案。

February 17, 2015	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
November 4, 2013	15-12B	- 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-33291 Optimer Pharmaceuticals, Inc. (Exact name of registrant as specif
October 24, 2013	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on October 24, 2013 Registration No.
October 24, 2013	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on October 24, 2013 Registration No.
October 24, 2013	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on October 24, 2013 Registration No.
October 24, 2013	EX-3.1	STATE of DELAWARE NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OPTIMER PHARMACEUTICALS, INC. Exhibit 3.1 STATE of DELAWARE NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OPTIMER PHARMACEUTICALS, INC. 1. Name. The name of this corporation is Optimer Pharmaceuticals, Inc. 2. Registered Office and Agent. The registered office of this corporation in the State of Delaware is located at 1209 Orange Street in the City of Wilmington 19801, County of New Castle. The name of its registe
October 24, 2013	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on October 24, 2013 Registration No.
October 24, 2013	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on October 24, 2013 Registration No.
October 24, 2013	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on October 24, 2013 Registration No.
October 24, 2013	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on October 24, 2013 Registration No.
October 24, 2013	POS AM	- POS AM As filed with the Securities and Exchange Commission on October 24, 2013 Registration No.
October 24, 2013	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 24, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Com
October 24, 2013	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on October 24, 2013 Registration No.
October 24, 2013	EX-3.2	SECOND AMENDED AND RESTATED BY-LAWS OPTIMER PHARMACEUTICALS, INC. Section 1. LAW, CERTIFICATE OF INCORPORATION AND BY-LAWS Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF OPTIMER PHARMACEUTICALS, INC. Section 1. LAW, CERTIFICATE OF INCORPORATION AND BY-LAWS 1.1. These by-laws are subject to the certificate of incorporation of the corporation. In these by-laws, references to law, the certificate of incorporation and by-laws mean the law, the provisions of the certificate of incorporation and the by-laws as from time
October 23, 2013	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 23, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Com
October 15, 2013	DEFA14A	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Com
October 15, 2013	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Com
October 10, 2013	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / PRICE T ROWE ASSOCIATES INC /MD/ - OPTR AS OF 09/30/2013 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* OPTIMER PHARMACEUTICALS (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68401H104 (CUSIP Number) September 30, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sch
September 18, 2013	EX-99.1	Dear Optimer colleagues: Exhibit 99.1 September 18, 2013 Dear Optimer colleagues: As announced in Optimer’s joint press release with Cubist on Friday morning, the antitrust waiting period applicable to the transaction with Cubist terminated on September 12. The expiration of the waiting period represents the satisfaction of one of the principal conditions to the closing of the transaction. In addition, Optimer has schedul
September 18, 2013	DEFA14A	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (C
September 18, 2013	425	Merger Prospectus - 425 Filed by Cubist Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Optimer Pharmaceuticals, Inc. Exchange Act Commission File No: 001-33291 September 18, 2013 Dear Optimer colleagues: As announced in Optimer’s joint press release with Cubist on Friday morning, the antitrust waiting period applicable to the transaction with Cubist terminated on
September 18, 2013	DEFM14A	- DEFM14A Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS TABLE OF CONTENTS 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 18, 2013	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (C
September 18, 2013	EX-99.1	Dear Optimer colleagues: EX-99.1 2 a13-208381ex99d1.htm EX-99.1 Exhibit 99.1 September 18, 2013 Dear Optimer colleagues: As announced in Optimer’s joint press release with Cubist on Friday morning, the antitrust waiting period applicable to the transaction with Cubist terminated on September 12. The expiration of the waiting period represents the satisfaction of one of the principal conditions to the closing of the transa
September 16, 2013	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 a13-2076518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporati
September 16, 2013	EX-3.1	CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A CONVERTIBLE PREFERRED STOCK, $0.001 PAR VALUE, OPTIMER PHARMACEUTICALS, INC. Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A CONVERTIBLE PREFERRED STOCK, $0.001 PAR VALUE, OF OPTIMER PHARMACEUTICALS, INC. The undersigned, Stephen W. Webster, Chief Financial Officer of OPTIMER PHARMACEUTICALS, INC. (the “Company”), a company organized and existing under the laws of the State of Delaware, does hereby certify: Pursuant to the authority conferred up
September 16, 2013	EX-10.1	SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT by and between OPTIMER PHARMACEUTICALS, INC. CUBIST PHARMACEUTICALS, INC. Dated as of September 16, 2013 Exhibit 10.1 EXECUTION VERSION SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT by and between OPTIMER PHARMACEUTICALS, INC. and CUBIST PHARMACEUTICALS, INC. Dated as of September 16, 2013 Table of Contents Page ARTICLE I DEFINITIONS Section 1.01 Definitions 1 Section 1.02 Accounting Procedures and Interpretation 5 ARTICLE II AGREEMENT TO SELL AND PURCHASE Section 2.01 Sale and Purchase 5 S
September 13, 2013	EX-99.1	HART-SCOTT-RODINO WAITING PERIOD EXPIRES FOR CUBIST ACQUISITION OF OPTIMER Exhibit 99.1 FOR IMMEDIATE RELEASE HART-SCOTT-RODINO WAITING PERIOD EXPIRES FOR CUBIST ACQUISITION OF OPTIMER Lexington, Mass. — September 13, 2013 — Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) in connection with the previously
September 13, 2013	EX-99.1	HART-SCOTT-RODINO WAITING PERIOD EXPIRES FOR CUBIST ACQUISITION OF OPTIMER Exhibit 99.1 FOR IMMEDIATE RELEASE HART-SCOTT-RODINO WAITING PERIOD EXPIRES FOR CUBIST ACQUISITION OF OPTIMER Lexington, Mass. — September 13, 2013 — Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) in connection with the previously
September 13, 2013	EX-99.1	HART-SCOTT-RODINO WAITING PERIOD EXPIRES FOR CUBIST ACQUISITION OF OPTIMER Exhibit 99.1 FOR IMMEDIATE RELEASE HART-SCOTT-RODINO WAITING PERIOD EXPIRES FOR CUBIST ACQUISITION OF OPTIMER Lexington, Mass. — September 13, 2013 — Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) in connection with the previously
September 13, 2013	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (C
September 13, 2013	425	Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 13, 2013 CUBIST PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 0-21379 22-3192085 (State or Other Jurisdiction of Incorporation) (Commissio
September 13, 2013	DEFA14A	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (C
September 10, 2013	EX-10.4	Disclosure of Agency Relationship Exhibit 10.4 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5t
September 10, 2013	EX-10.7	Disclosure of Agency Relationship EX-10.7 10 a13-204671ex10d7.htm EX-10.7 Exhibit 10.7 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: Morgan Stanley & Co. International plc c/o Mo
September 10, 2013	EX-99.1	CUBIST PHARMACEUTICALS ISSUES $800 MILLION OF CONVERTIBLE SENIOR NOTES Exhibit 99.1 Filed by Cubist Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Optimer Pharmaceuticals, Inc. Exchange Act Commission File No: 001-33291 FOR IMMEDIATE RELEASE CUBIST PHARMACEUTICALS ISSUES $800 MILLION OF CONVERTIBLE SENIOR NOTES Lexington, Mass. — September 10, 2013 — Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced
September 10, 2013	EX-10.12	Disclosure of Agency Relationship Exhibit 10.12 RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: RBC Capital Markets, LLC as agent for Royal Bank of Canada TELEPHONE: (212) 85
September 10, 2013	EX-4.1	CUBIST PHARMACEUTICALS, INC. 1.125% CONVERTIBLE SENIOR NOTES DUE 2018 INDENTURE DATED AS OF SEPTEMBER 10, 2013 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE EX-4.1 2 a13-204671ex4d1.htm EX-4.1 Exhibit 4.1 EXECUTION VERSION CUBIST PHARMACEUTICALS, INC. 1.125% CONVERTIBLE SENIOR NOTES DUE 2018 INDENTURE DATED AS OF SEPTEMBER 10, 2013 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 8 Section 1.03. Rules of Co
September 10, 2013	EX-10.1	Disclosure of Agency Relationship EX-10.1 4 a13-204671ex10d1.htm EX-10.1 Exhibit 10.1 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: Morgan Stanley & Co. International plc c/o Mor
September 10, 2013	EX-10.2	Disclosure of Agency Relationship EX-10.2 5 a13-204671ex10d2.htm EX-10.2 Exhibit 10.2 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Ave New York, NY 10019 Telephone: +1 212 412 4000 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 0242
September 10, 2013	EX-10.10	Disclosure of Agency Relationship EX-10.10 13 a13-204671ex10d10.htm EX-10.10 Exhibit 10.10 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: Morgan Stanley & Co. International plc c/
September 10, 2013	EX-10.8	Disclosure of Agency Relationship Exhibit 10.8 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Ave New York, NY 10019 Telephone: +1 212 412 4000 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE:
September 10, 2013	EX-4.2	CUBIST PHARMACEUTICALS, INC. 1.875% CONVERTIBLE SENIOR NOTES DUE 2020 INDENTURE DATED AS OF SEPTEMBER 10, 2013 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE EX-4.2 3 a13-204671ex4d2.htm EX-4.2 Exhibit 4.2 EXECUTION VERSION CUBIST PHARMACEUTICALS, INC. 1.875% CONVERTIBLE SENIOR NOTES DUE 2020 INDENTURE DATED AS OF SEPTEMBER 10, 2013 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 8 Section 1.03. Rules of Co
September 10, 2013	425	Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 5, 2013 CUBIST PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 0-21379 22-3192085 (State or Other Jurisdiction of Incorporation) (Commission
September 10, 2013	EX-10.3	Disclosure of Agency Relationship Exhibit 10.3 RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: RBC Capital Markets, LLC as agent for Royal Bank of Canada TELEPHONE: (212) 858
September 10, 2013	EX-10.5	Disclosure of Agency Relationship Exhibit 10.5 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Ave New York, NY 10019 Telephone: +1 212 412 4000 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE:
September 10, 2013	EX-10.6	Disclosure of Agency Relationship Exhibit 10.6 RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: RBC Capital Markets, LLC as agent for Royal Bank of Canada TELEPHONE: (212) 858
September 10, 2013	EX-10.11	Disclosure of Agency Relationship EX-10.11 14 a13-204671ex10d11.htm EX-10.11 Exhibit 10.11 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Ave New York, NY 10019 Telephone: +1 212 412 4000 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts
September 10, 2013	EX-10.9	Disclosure of Agency Relationship EX-10.9 12 a13-204671ex10d9.htm EX-10.9 Exhibit 10.9 RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 DATE: September 5, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: RBC Capital Markets, LLC as agent for R
September 5, 2013	EX-10.1	Disclosure of Agency Relationship Exhibit 10.1 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5t
September 5, 2013	425	Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 3, 2013 CUBIST PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 0-21379 22-3192085 (State or Other Jurisdiction of Incorporation) (Commission
September 5, 2013	EX-10.12	Disclosure of Agency Relationship Exhibit 10.12 RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: RBC Capital Markets, LLC as agent for Royal Bank of Canada TELEPHONE: (212) 85
September 5, 2013	EX-10.3	Disclosure of Agency Relationship Exhibit 10.3 RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: RBC Capital Markets, LLC as agent for Royal Bank of Canada TELEPHONE: (212) 858
September 5, 2013	EX-10.6	Disclosure of Agency Relationship Exhibit 10.6 RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: RBC Capital Markets, LLC as agent for Royal Bank of Canada TELEPHONE: (212) 858
September 5, 2013	EX-10.8	Disclosure of Agency Relationship Exhibit 10.8 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Ave New York, NY 10019 Telephone: +1 212 412 4000 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE:
September 5, 2013	EX-10.11	Disclosure of Agency Relationship Exhibit 10.11 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Ave New York, NY 10019 Telephone: +1 212 412 4000 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE
September 5, 2013	EX-10.2	Disclosure of Agency Relationship Exhibit 10.2 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Ave New York, NY 10019 Telephone: +1 212 412 4000 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE:
September 5, 2013	EX-99.1	CUBIST PHARMACEUTICALS PRICES $700 MILLION OF CONVERTIBLE SENIOR NOTES Exhibit 99.1 Filed by Cubist Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Optimer Pharmaceuticals, Inc. Exchange Act Commission File No: 001-33291 FOR IMMEDIATE RELEASE CUBIST PHARMACEUTICALS PRICES $700 MILLION OF CONVERTIBLE SENIOR NOTES Lexington, Mass. — September 5, 2013 — Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced t
September 5, 2013	EX-10.7	Disclosure of Agency Relationship Exhibit 10.7 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5t
September 5, 2013	EX-10.9	Disclosure of Agency Relationship Exhibit 10.9 RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: RBC Capital Markets, LLC as agent for Royal Bank of Canada TELEPHONE: (212) 858
September 5, 2013	EX-10.5	Disclosure of Agency Relationship EX-10.5 7 a13-185513ex10d5.htm EX-10.5 Exhibit 10.5 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Ave New York, NY 10019 Telephone: +1 212 412 4000 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 0242
September 5, 2013	EX-10.10	Disclosure of Agency Relationship Exhibit 10.10 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5
September 5, 2013	EX-1.1	CUBIST PHARMACEUTICALS, INC. 1.125% CONVERTIBLE SENIOR NOTES DUE 2018 1.875% CONVERTIBLE SENIOR NOTES DUE 2020 PURCHASE AGREEMENT Exhibit 1.1 EXECUTION VERSION CUBIST PHARMACEUTICALS, INC. 1.125% CONVERTIBLE SENIOR NOTES DUE 2018 1.875% CONVERTIBLE SENIOR NOTES DUE 2020 PURCHASE AGREEMENT September 4, 2013 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 RBC Capital Markets, LLC Three World Financial Center 200 Vesey Street New York, New York 10
September 5, 2013	EX-10.4	Disclosure of Agency Relationship Exhibit 10.4 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 DATE: September 4, 2013 TO: Cubist Pharmaceuticals, Inc. 65 Hayden Avenue Lexington, Massachusetts 02421 ATTENTION: General Counsel TELEPHONE: (781) 860-8660 FACSIMILE: (781) 240-1076 FROM: Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5t
August 22, 2013	DEFA14A	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 22, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Comm
August 22, 2013	EX-99.1	SUPPLEMENTAL QUESTIONS AND ANSWERS FOR EMPLOYEES Exhibit 99.1 SUPPLEMENTAL QUESTIONS AND ANSWERS FOR EMPLOYEES This Supplemental Q&A addresses some common questions that have been raised following the announcement of the Merger with Cubist (the “Merger”). It is intended to supplement, not replace, the first set of questions and answers (numbered 1 through 35) circulated to Optimer employees on July 30, 2013. It is meant to be a helpful guide onl
August 22, 2013	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 22, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Comm
August 22, 2013	EX-99.1	SUPPLEMENTAL QUESTIONS AND ANSWERS FOR EMPLOYEES Exhibit 99.1 SUPPLEMENTAL QUESTIONS AND ANSWERS FOR EMPLOYEES This Supplemental Q&A addresses some common questions that have been raised following the announcement of the Merger with Cubist (the “Merger”). It is intended to supplement, not replace, the first set of questions and answers (numbered 1 through 35) circulated to Optimer employees on July 30, 2013. It is meant to be a helpful guide onl
August 7, 2013	EX-10.3	101 HUDSON STREET, SUITE 3501, JERSEY CITY, NJ 07302 TEL: 201-333-8819 FAX: 201-333-8870 Exhibit 10.3 May 9, 2013 Eric Sirota 12 Edgehill Avenue Chatham, NJ 07928 Dear Eric: It is with great pleasure that I offer you the position of Chief Operating Officer with Optimer Pharmaceuticals, Inc. (“Optimer” or the “Company”), performing such duties as are normally associated with this position and such duties as are assigned to you from time to time. You will report to Hank McKinnell, Optim
August 7, 2013	EX-10.2	AMENDMENT # 4 TO API MANUFACTURING AND SUPPLY AGREEMENT Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. AMENDMENT # 4 TO API MANUFACTURING AND SUPPLY AGREEMENT This Amendment # 4 to API Manufacturing and Supply Agreement (this “Amendment # 4”), is entered into as of April 29, 2013 by and between Optimer Pharmaceuticals, I
August 7, 2013	EX-10.1	EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT Exhibit 10.1 February 26, 2013 Henry A. McKinnell, Ph.D. 3 Creek Ranch PO Box 524 Jackson, WY 83001 Dear Hank: I am pleased to confirm the terms of your position as Chief Executive Officer of Optimer Pharmaceuticals, Inc. (the “Company”). 1. Effective Date. February 26, 2013. 2. Position. Your service as Chief Executive Officer of the Company began on the Effective Date. In that capacity, you repo
August 7, 2013	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33291 OPTI
August 2, 2013	EX-99.1	Optimer Reports Second Quarter 2013 Financial Results $20.1 million in total net revenues for Q2 2013 Exhibit 99.1 Optimer Reports Second Quarter 2013 Financial Results $20.1 million in total net revenues for Q2 2013 JERSEY CITY, New Jersey, August 1, 2013 — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the second quarter ended June 30, 2013. Financial Highlights · Second quarter 2013 DIFICID net product sales in the U.S. and Canada of $19.0 million,
August 2, 2013	425	Merger Prospectus - 425 Filed by Cubist Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Optimer Pharmaceuticals, Inc. Exchange Act Commission File No: 001-33291 Date Dear Dr. XXX; Earlier this week, Cubist announced our planned acquisitions of both Trius Therapeutics and Optimer Pharmaceuticals. As a key infectious disease expert, we thought it important to convey
August 2, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2013 OPTIMER PHARMACEUTICALS, INC.
August 1, 2013	EX-10.2	AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT Exhibit 10.2 AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT This AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT (the “Amendment”) is entered into on July 30, 2013 (the “Amendment Effective Date”), by and among Cubist Pharmaceuticals, Inc. (“Cubist”) and Optimer Pharmaceuticals, Inc. (“Optimer”). Cubist and Optimer may each be referred to herein individually as a “Party” and collectively as the “Parties.” Ca
August 1, 2013	EX-10.1	- EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT by and between Cubist Pharmaceuticals, Inc. and [TRUSTEE] Dated as of [·], 2013 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION Section 1.1 Definitions 1 Section 1.2 Termination 9 Section 1.3 Compliance and Opinions 9 Section 1.4 Form of Documents Delivered to Trustee 10 Section 1.5 Acts of Holders 10 Section 1
August 1, 2013	EX-10.1	CONTINGENT VALUE RIGHTS AGREEMENT by and between Cubist Pharmaceuticals, Inc. Dated as of [·], 2013 EX-10.1 3 a13-175586ex10d1.htm EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT by and between Cubist Pharmaceuticals, Inc. and [TRUSTEE] Dated as of [·], 2013 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION Section 1.1 Definitions 1 Section 1.2 Termination 9 Section 1.3 Compliance and Opinions 9 Section 1.4 Form of Documents Delivered to Trustee 10 S
August 1, 2013	EX-2.1	AGREEMENT AND PLAN OF MERGER OPTIMER PHARMACEUTICALS, INC., CUBIST PHARMACEUTICALS, INC. PDRS CORPORATION Dated as of July 30, 2013 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among OPTIMER PHARMACEUTICALS, INC., CUBIST PHARMACEUTICALS, INC. and PDRS CORPORATION Dated as of July 30, 2013 TABLE OF CONTENTS Page ARTICLE I The Merger; Closing; Effective Time 1.1. The Merger 1 1.2. Closing 1 1.3. Effective Time 2 1.4. Subsequent Action 2 ARTICLE II Certificate of Incorporation and By-Laws of the Surviving Corporatio
August 1, 2013	EX-99.1	Safe Harbor Statement 2 This presentation and statements in this conference call regarding the proposed transactions contain forward-looking statements. Any statements contained herein which do not describe historical facts, including but not limited Planned Acquisitions of Trius Therapeutics and Optimer Pharmaceuticals Accelerating Cubist’s Global Leadership in Acute Care July 30, 2013 Exhibit 99.
August 1, 2013	EX-2.1	AGREEMENT AND PLAN OF MERGER OPTIMER PHARMACEUTICALS, INC., CUBIST PHARMACEUTICALS, INC. PDRS CORPORATION Dated as of July 30, 2013 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among OPTIMER PHARMACEUTICALS, INC., CUBIST PHARMACEUTICALS, INC. and PDRS CORPORATION Dated as of July 30, 2013 TABLE OF CONTENTS Page ARTICLE I The Merger; Closing; Effective Time 1.1. The Merger 1 1.2. Closing 1 1.3. Effective Time 2 1.4. Subsequent Action 2 ARTICLE II Certificate of Incorporation and By-Laws of the Surviving Corporatio
August 1, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Commis
August 1, 2013	EX-10.2	AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT EX-10.2 4 a13-175586ex10d2.htm EX-10.2 Exhibit 10.2 AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT This AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT (the “Amendment”) is entered into on July 30, 2013 (the “Amendment Effective Date”), by and among Cubist Pharmaceuticals, Inc. (“Cubist”) and Optimer Pharmaceuticals, Inc. (“Optimer”). Cubist and Optimer may each be referred to herein individually as a “Party
August 1, 2013	425	Merger Prospectus - 425 Filed by Cubist Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Optimer Pharmaceuticals, Inc. Exchange Act Commission File No: 001-33291 CUBIST PHARMACEUTICALS, INC. 07-30-13/6:00 p.m. EST The following is a transcript of an investor presentation given by Cubist Pharmaceuticals, Inc. (“Cubist”) on July 30, 2013, in connection with the Cubist
August 1, 2013	EX-10.2	- EX-10.2 Exhibit 10.2 AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT This AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT (the “Amendment”) is entered into on July 30, 2013 (the “Amendment Effective Date”), by and among Cubist Pharmaceuticals, Inc. (“Cubist”) and Optimer Pharmaceuticals, Inc. (“Optimer”). Cubist and Optimer may each be referred to herein individually as a “Party” and collectively as the “Parties.” Ca
August 1, 2013	EX-2.1	AGREEMENT AND PLAN OF MERGER OPTIMER PHARMACEUTICALS, INC., CUBIST PHARMACEUTICALS, INC. PDRS CORPORATION Dated as of July 30, 2013 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among OPTIMER PHARMACEUTICALS, INC., CUBIST PHARMACEUTICALS, INC. and PDRS CORPORATION Dated as of July 30, 2013 TABLE OF CONTENTS Page ARTICLE I The Merger; Closing; Effective Time 1.1. The Merger 1 1.2. Closing 1 1.3. Effective Time 2 1.4. Subsequent Action 2 ARTICLE II Certificate of Incorporation and By-Laws of the Surviving Corporatio
August 1, 2013	425	Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) July 30, 2013 CUBIST PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 0-21379 22-3192085 (State or Other Jurisdiction of Incorporation) (Commission Fil
August 1, 2013	EX-10.1	CONTINGENT VALUE RIGHTS AGREEMENT by and between Cubist Pharmaceuticals, Inc. Dated as of [·], 2013 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT by and between Cubist Pharmaceuticals, Inc. and [TRUSTEE] Dated as of [·], 2013 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION Section 1.1 Definitions 1 Section 1.2 Termination 9 Section 1.3 Compliance and Opinions 9 Section 1.4 Form of Documents Delivered to Trustee 10 Section 1.5 Acts of Holders 10 Section 1
August 1, 2013	DEFA14A	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Commis
July 30, 2013	DEFA14A	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Commis
July 30, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Commis
July 30, 2013	EX-99.3	To All Optimer Employees, Exhibit 99.3 To All Optimer Employees, I’ve asked that Hank share this brief note with all of you today, as I’m sure you have already heard that this afternoon we jointly announced that Cubist has agreed to acquire Optimer. It’s an exciting time for both of our companies, and on behalf of my colleagues, I want to extend my warmest greetings to each of you. We believe this transaction represents a
July 30, 2013	DEFA14A	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Commis
July 30, 2013	EX-99.1	CUBIST PHARMACEUTICALS TO ACQUIRE OPTIMER PHARMACEUTICALS Transaction Adds Complementary Antibacterial Drug DIFICID® for CDAD and Bolsters Cubist’s Leadership in Acute Care Hospital Market Transaction Expected to be Accretive in First Year Post Closi Exhibit 99.1 CUBIST PHARMACEUTICALS TO ACQUIRE OPTIMER PHARMACEUTICALS Transaction Adds Complementary Antibacterial Drug DIFICID® for CDAD and Bolsters Cubist’s Leadership in Acute Care Hospital Market Transaction Expected to be Accretive in First Year Post Closing DIFICID Co-Promote Agreement Extended Lexington, Mass., and Jersey City, NJ – July 30, 2013 – Cubist Pharmaceuticals, Inc. (NASDAQ: CB
July 30, 2013	EX-99.1	Questions and Answers for U.S. Employees Exhibit 99.1 July 30, 2013 Dear Optimer colleagues: Over the last few months, our Board of Directors has conducted a review of strategic alternatives available to the Company. The Board carefully evaluated several alternatives, including the option to continue as an independent Company. The Board decided that the best way to maximize value for stockholders was to enter into an agreement with Cubis
July 30, 2013	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-33291 33-0830300 (Commis
July 30, 2013	EX-99.1	Cubist Pharmaceuticals to Acquire Optimer Pharmaceuticals Transaction Adds Complementary Antibacterial Drug DIFICID® for CDAD and Bolsters Cubist’s Leadership in Acute Care Hospital Market Transaction Expected to be Accretive in First Year Post Closi Exhibit 99.1 Cubist Pharmaceuticals to Acquire Optimer Pharmaceuticals Transaction Adds Complementary Antibacterial Drug DIFICID® for CDAD and Bolsters Cubist’s Leadership in Acute Care Hospital Market Transaction Expected to be Accretive in First Year Post Closing DIFICID Co-Promote Agreeement Extended Lexington, Mass., and Jersey City, NJ – July 30, 2013 – Cubist Pharmaceuticals, Inc. (NASDAQ: C
July 30, 2013	EX-99.1	Questions and Answers for U.S. Employees Exhibit 99.1 July 30, 2013 Dear Optimer colleagues: Over the last few months, our Board of Directors has conducted a review of strategic alternatives available to the Company. The Board carefully evaluated several alternatives, including the option to continue as an independent Company. The Board decided that the best way to maximize value for stockholders was to enter into an agreement with Cubis
July 30, 2013	425	Merger Prospectus - 8-K 425 1 a13-1755838k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) July 30, 2013 CUBIST PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 0-21379 22-3192085 (State or Other Jurisdiction of Inc
July 30, 2013	EX-99.1	Cubist Pharmaceuticals to Acquire Optimer Pharmaceuticals Transaction Adds Complementary Antibacterial Drug DIFICID® for CDAD and Bolsters Cubist’s Leadership in Acute Care Hospital Market Transaction Expected to be Accretive in First Year Post Closi Exhibit 99.1 Cubist Pharmaceuticals to Acquire Optimer Pharmaceuticals Transaction Adds Complementary Antibacterial Drug DIFICID® for CDAD and Bolsters Cubist’s Leadership in Acute Care Hospital Market Transaction Expected to be Accretive in First Year Post Closing DIFICID Co-Promote Agreeement Extended Lexington, Mass., and Jersey City, NJ – July 30, 2013 – Cubist Pharmaceuticals, Inc. (NASDAQ: C
July 30, 2013	EX-99.3	To All Optimer Employees, Exhibit 99.3 To All Optimer Employees, I’ve asked that Hank share this brief note with all of you today, as I’m sure you have already heard that this afternoon we jointly announced that Cubist has agreed to acquire Optimer. It’s an exciting time for both of our companies, and on behalf of my colleagues, I want to extend my warmest greetings to each of you. We believe this transaction represents a
July 30, 2013	EX-99.2	Questions and Answers Exhibit 99.2 July 30, 2013 Dear Optimer colleagues: Over the last few months, our Board of Directors has conducted a review of strategic alternatives available to the Company. The Board carefully evaluated several alternatives, including the option to continue as an independent Company. The Board decided that the best way to maximize value for stockholders was to enter into an agreement with Cubis
July 30, 2013	EX-99.2	Questions and Answers Exhibit 99.2 July 30, 2013 Dear Optimer colleagues: Over the last few months, our Board of Directors has conducted a review of strategic alternatives available to the Company. The Board carefully evaluated several alternatives, including the option to continue as an independent Company. The Board decided that the best way to maximize value for stockholders was to enter into an agreement with Cubis
May 24, 2013	SC 13G	OPTR / Optimer Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
May 13, 2013	EX-99.1	OPTIMER PHARMACEUTICALS APPOINTS ERIC SIROTA AS CHIEF OPERATING OFFICER Exhibit 99.1 OPTIMER PHARMACEUTICALS APPOINTS ERIC SIROTA AS CHIEF OPERATING OFFICER JERSEY CITY, May 13, 2013 — Optimer Pharmaceuticals (NASDAQ: OPTR) (the “Company” or “Optimer”) today announced the appointment of Mr. Eric Sirota as Chief Operating Officer. Mr. Sirota will be responsible for directing Optimer’s corporate strategy with regard to DIFICID®. “Eric has tremendous experience and has d
May 13, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2013 OPTIMER PHARMACEUTICALS, INC.
May 10, 2013	EX-10.6	OPTIMER PHARMACEUTICALS, INC. AMENDED AND RESTATED SEVERANCE BENEFIT PLAN Exhibit 10.6 OPTIMER PHARMACEUTICALS, INC. AMENDED AND RESTATED SEVERANCE BENEFIT PLAN Section 1. INTRODUCTION. The Optimer Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan (the “Plan”) was originally established effective May 5, 2010 amended and restated effective February 7, 2012 and is hereby further amended and restated in its entirety effective February 26, 2013 (the “Effecti
May 10, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33291 OPT
May 10, 2013	EX-10.5	EMPLOYEE PROPRIETARY INFORMATION AGREEMENT Exhibit 10.5 March 4, 2013 Pedro Lichtinger 7211 Eads Ave La Jolla, CA 92037 Re: Separation from Optimer Pharmaceuticals, Inc. Dear Mr. Lichtinger: This letter sets forth the terms and conditions of the separation agreement (the “Agreement”) that OPTIMER PHARMACEUTICALS, INC. (the “Company”) is offering to aid in your employment transition. This Agreement shall be effective as of the Effective Dat
May 9, 2013	EX-99.1	Optimer Reports First Quarter 2013 Financial Results $19.4 million in total net revenues for Q1 2013 Exhibit 99.1 Optimer Reports First Quarter 2013 Financial Results $19.4 million in total net revenues for Q1 2013 JERSEY CITY, New Jersey, May 9, 2013 — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the first quarter ended March 31, 2013. Financial Highlights · First quarter 2013 DIFICID net product sales in the U.S. and Canada of $16.8 million, compa
May 9, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2013 OPTIMER PHARMACEUTICALS, INC.
May 8, 2013	8-K	Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2013 OPTIMER PHARMACEUTICALS, INC.
April 19, 2013	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
April 12, 2013	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
March 18, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33291 Optimer Pharmaceuticals, Inc.
March 18, 2013	EX-21.1	JURISDICTION OF INCORPORATION: Exhibit 21.1 Subsidiaries of Optimer Pharmaceuticals, Inc.: NAME: JURISDICTION OF INCORPORATION: Optimer Pharmaceuticals U.S. Holdings LLC United States Optimer Pharmaceuticals Canada, Inc. Canada Optimer Luxembourg 1 S.?.r.l. Europe Optimer Luxembourg 2 S.?.r.l. Europe Optimer Bermuda LP Bermuda
March 18, 2013	EX-10.46	2 Exhibit 10.46 December 11, 2012 Mr. Gregory Papaz 53 Stone Ridge Drive Ringwood, NJ 07456 Re: Separation Agreement from Optimer Pharmaceuticals, Inc. Dear Greg: This letter sets forth the terms and conditions of the separation agreement (the ?Agreement?) that OPTIMER PHARMACEUTICALS, INC. (the ?Company?) is offering to aid in your employment transition. This Agreement shall be effective as of the
March 18, 2013	EX-10.45	SUPPLEMENTAL AGREEMENT REGARDING INTELLECTUAL PROPERTY ASSIGNMENT AND LICENSE AGREEMENT Exhibit 10.45 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. SUPPLEMENTAL AGREEMENT REGARDING INTELLECTUAL PROPERTY ASSIGNMENT AND LICENSE AGREEMENT This Supplemental Agreement Regarding Intellectual Property Assignment and License Agreement (the “Supplement”) is made and effect
March 18, 2013	EX-10.44	STOCK PURCHASE AGREEMENT by and among HUEI HONG INVESTMENT CO., LTD. CHANG CHUEN INVESTMENT CO., LTD. YI TAI INVESTMENT CO., LTD. YUAN HONG INVESTMENT CO., LTD. OPTIMER PHARMACEUTICALS, INC. Dated as of October 5, 2012 Exhibit 10.44 CONFIDENTIAL Execution Copy STOCK PURCHASE AGREEMENT by and among HUEI HONG INVESTMENT CO., LTD. CHANG CHUEN INVESTMENT CO., LTD. YI TAI INVESTMENT CO., LTD. YUAN HONG INVESTMENT CO., LTD. and OPTIMER PHARMACEUTICALS, INC. Dated as of October 5, 2012 Table of Contents Page Article I CLOSING TIME TRANSACTIONS Section 1.1 Sale and Purchase of the Seller Shares 1 Section 1.2 Closings 1
March 18, 2013	EX-10.49	March 1, 2013 Exhibit 10.49 March 1, 2013 Kurt Hartman 1 Austen Court Marlboro, NJ 07746 Re: Separation from Optimer Pharmaceuticals, Inc. Dear Mr. Hartman: This letter sets forth the terms and conditions of the separation agreement (the “Agreement”) that OPTIMER PHARMACEUTICALS, INC. (the “Company”) is offering to aid in your employment transition. This Agreement shall be effective as of the date you sign this
March 1, 2013	8-A12B	- 8-A12B SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 33-0830300 (I.R.S. Employer Identification No.) 101 Hudson Street, S
March 1, 2013	NT 10-K	- NT 10-K OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . . . . . . 2.50 SEC FILE NUMBER 001-33291 CUSIP NUMBER 68401H104 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: D
February 28, 2013	EX-99.1	Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results Optimer reports $62.4 million in DIFICID® (fidaxomicin) tablets net product sales for 2012 Exhibit 99.1 Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results Optimer reports $62.4 million in DIFICID® (fidaxomicin) tablets net product sales for 2012 JERSEY CITY, New Jersey, February 28, 2013 — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the fourth quarter and fiscal year ended December 31, 2012. Financial Highlights · 2012
February 28, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2013 OPTIMER PHARMACEUTICALS, INC.
February 28, 2013	EX-99.2	Q4 and Fiscal Year 2012 Optimer Pharmaceuticals Earnings Conference Call Script Exhibit 99.2 Q4 and Fiscal Year 2012 Optimer Pharmaceuticals Earnings Conference Call Script OPERATOR: Ladies and gentlemen, thank you for standing by for Optimer Pharmaceuticals’ conference call. I would like to remind you that this call is being recorded. At this time, I would like to turn the call over to David Walsey, Optimer’s Vice President of Investor Relations and Corporate Communications.
February 27, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2013 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33291 (Commission Fi
February 27, 2013	EX-10.1	Board of Directors of Optimer Pharmaceuticals, Inc., Exhibit 10.1 February 26, 2013 Board of Directors of Optimer Pharmaceuticals, Inc., 101 Hudson Street, Suite 3501, Jersey City, NJ 07302. Fellow Members of the Board, I defer to your decision to appoint Hank McKinnell as Chief Executive Officer and, subject to your acceptance, resign as both an officer and director of Optimer Pharmaceuticals, Inc. This letter confirms the understanding that my res
February 27, 2013	EX-99.1	OPTIMER PHARMACEUTICALS’ BOARD OF DIRECTORS APPOINTS BOARD CHAIRMAN, DR. HENRY MCKINNELL, CHIEF EXECUTIVE OFFICER COMPANY TO EXPLORE STRATEGIC ALTERNATIVES Exhibit 99.1 OPTIMER PHARMACEUTICALS’ BOARD OF DIRECTORS APPOINTS BOARD CHAIRMAN, DR. HENRY MCKINNELL, CHIEF EXECUTIVE OFFICER COMPANY TO EXPLORE STRATEGIC ALTERNATIVES JERSEY CITY, February 27, 2013—The Board of Directors of Optimer Pharmaceuticals (NASDAQ: OPTR) (the “Company” or “Optimer”) today announced the appointment of its Chairman, Dr. Henry McKinnell, as Chief Executive Officer. Dr. McKi
February 27, 2013	EX-10.2	Board of Directors of Optimer Pharmaceuticals, Inc., Exhibit 10.2 February 26, 2013 Board of Directors of Optimer Pharmaceuticals, Inc., 101 Hudson Street, Suite 3501, Jersey City, NJ 07302. Members of the Board, I defer to your decision to appoint Meredith Schaum as General Counsel and, subject to your acceptance, resign as General Counsel, Chief Compliance Officer, Senior Vice President and Secretary of Optimer Pharmaceuticals, Inc. This letter co
February 27, 2013	EX-4.1	STOCKHOLDER PROTECTION RIGHTS AGREEMENT dated as of February 26, 2013 OPTIMER PHARMACEUTICALS, INC. AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Rights Agent EXHIBIT 4.1 STOCKHOLDER PROTECTION RIGHTS AGREEMENT dated as of February 26, 2013 between OPTIMER PHARMACEUTICALS, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Rights Agent STOCKHOLDER PROTECTION RIGHTS AGREEMENT Table of Contents Page ARTICLE I DEFINITIONS 1.1 Definitions 2 ARTICLE II THE RIGHTS 2.1 Summary of Rights 14 2.2 Legend 14 2.3 Exercise of Rights; Separation of Rights 15 2.
February 14, 2013	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / SECTORAL ASSET MANAGEMENT INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OPTIMER PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68401H104 (CUSIP Number) DECEMBER 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 14, 2013	SC 13G	OPTR / Optimer Pharmaceuticals Inc / WELLINGTON MANAGEMENT GROUP LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Optimer Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68401H104 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 13, 2013	SC 13G	OPTR / Optimer Pharmaceuticals Inc / VANGUARD GROUP INC Passive Investment optimerpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Optimer Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 68401H104 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check th
February 11, 2013	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / PRICE T ROWE ASSOCIATES INC /MD/ - OPTR AS OF 01/31/2013 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* OPTIMER PHARMACEUTICALS (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68401H104 (CUSIP Number) January 31, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sched
February 7, 2013	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / PRICE T ROWE ASSOCIATES INC /MD/ - OPTR AS OF 12/31/2012 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OPTIMER PHARMACEUTICALS (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68401H104 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sche
January 25, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 22, 2013 OPTIMER PHARMACEUTICALS, INC.
January 7, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 7, 2013 OPTIMER PHARMACEUTICALS, INC.
January 7, 2013	EX-99.1	Optimer Pharmaceuticals Reports Preliminary 2012 Gross Product Sales of $74.4 Million 4th Quarter 2012 Gross DIFICID® Sales of $21.3 Million, Up 74.7% Over 4th Quarter 2011 and 14.4% Above the 3rd Quarter of 2012 Optimer Launches DIFICID Co-Pay Assis Exhibit 99.1 Optimer Pharmaceuticals Reports Preliminary 2012 Gross Product Sales of $74.4 Million 4th Quarter 2012 Gross DIFICID® Sales of $21.3 Million, Up 74.7% Over 4th Quarter 2011 and 14.4% Above the 3rd Quarter of 2012 Optimer Launches DIFICID Co-Pay Assistance Program and Announces Price Increase Jersey City, NJ — January 7, 2013 — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today provide
December 11, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2012 OPTIMER PHARMACEUTICALS, INC.
November 13, 2012	S-8	- S-8 As filed with the Securities and Exchange Commission on November 13, 2012 Registration No.
November 7, 2012	EX-99.1	OPTIMER PHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 29, 2012 AMENDED BY THE BOARD OF DIRECTORS: MARCH 27, 2012 APPROVED BY THE STOCKHOLDERS: MAY 9, 2012 AMENDED BY THE BOARD OF DIRECTORS: NOVEMBER 2, 2 Exhibit 99.1 OPTIMER PHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 29, 2012 AMENDED BY THE BOARD OF DIRECTORS: MARCH 27, 2012 APPROVED BY THE STOCKHOLDERS: MAY 9, 2012 AMENDED BY THE BOARD OF DIRECTORS: NOVEMBER 2, 2012 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Optimer
November 7, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2012 OPTIMER PHARMACEUTICALS, INC.
November 2, 2012	EX-10.2	THIRD AMENDMENT TO API MANUFACTURING AND SUPPLY AGREEMENT Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 THIRD AMENDMENT TO API MANUFACTURING AND SUPPLY AGREEMENT This Third Amendment (this “Third Amendment”) dated as of the 10th day of September, 2012 (the “Third Amendment Date”), is made by and between Biocon Limited (“Bi
November 2, 2012	EX-10.1	Pedro Lichtinger Exhibit 10.1 AG2012/4417-2012-1019 Pedro Lichtinger Chief Executive Officer Optimer Pharmaceuticals Inc 5355 Mira Sorrento Place Suite 250 - West Tower San Diego, California. 92121 USA 6 September 2012 Dear Pedro Collaboration and License Agreement between Optimer Pharmaceuticals Inc and Astellas Pharma Europe Limited dated 2 February 2011 (the ?Collaboration Agreement?) Amendment No 1 In accordan
November 2, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a12-20021110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co
November 1, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2012 OPTIMER PHARMACEUTICALS, INC.
November 1, 2012	EX-99.1	Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results Webcast and Conference Call Today at 5:00 p.m. Eastern Time Exhibit 99.1 Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results Webcast and Conference Call Today at 5:00 p.m. Eastern Time Jersey City, NJ — November 1, 2012 — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company’s financial results for the quarter ended September 30, 2012. Third Quarter 2012 Financial Highlights: · DIFICID® gross sales in the U.S. and Canada
October 9, 2012	EX-99.2	1 Exhibit 99.2 Optimer Pharmaceuticals, Inc. OPTR Analyst and Investor Day Oct. 8, 2012 Companyp Tickerp Event Typep Datep · PARTICIPANTS Corporate Participants David A. Walsey – VP-Investor Relations & Corporate Communications Pedro Lichtinger – President, Chief Executive Officer & Director Stephen W. Webster – Chief Financial Officer & Senior Vice President, Finance Hemal Shah – Senior Vice Presid
October 9, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets 8-K 1 a12-2308618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2012 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33291 33-0830300 (State or other jurisdiction
October 9, 2012	EX-99.1	Optimer Pharmaceuticals to Sell Remaining Ownership in Optimer Biotechnology, Inc. for U.S. $60 Million Optimer also announces top-line third quarter U.S. gross DIFICID® sales and schedules third quarter financial results conference call for November Exhibit 99.1 Optimer Pharmaceuticals to Sell Remaining Ownership in Optimer Biotechnology, Inc. for U.S. $60 Million Optimer also announces top-line third quarter U.S. gross DIFICID® sales and schedules third quarter financial results conference call for November 1, 2012 SAN DIEGO, CA — October 8, 2012 —Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the sale of its stake in Optimer B
August 3, 2012	EX-10.7	OPTIMER PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Exhibit 10.7 OPTIMER PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Optimer Pharmaceuticals, Inc. (the “Company”) hereby awards to Participant the number of restricted stock units specified and on the terms set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2012 Equity Incentive Plan
August 3, 2012	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2012 OPTIMER PHARMACEUTICALS, INC.
August 3, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33291 OPTI
August 3, 2012	EX-10.2	AMENDMENT TO API MANUFACTURING AND SUPPLY AGREEMENT Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. AMENDMENT TO API MANUFACTURING AND SUPPLY AGREEMENT This AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT (this “Amendment”), is entered into as of May 20, 2011 by and between OPTIMER PHARMACEUTICALS, INC. (“Optimer”) an
August 3, 2012	EX-10.5	OPTIMER PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Exhibit 10.5 OPTIMER PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Optimer Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2012 Equity Incentive Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this
August 3, 2012	EX-99.1	CMS Grants New Technology Add-on Payment to DIFICID® for Treatment of Clostridium difficile-associated Diarrhea Add-on Payment to Provide Additional Medicare Reimbursement up to 50% of the Cost of DIFICID Prescribed in Inpatient Setting Webcast and C Exhibit 99.1 CMS Grants New Technology Add-on Payment to DIFICID® for Treatment of Clostridium difficile-associated Diarrhea Add-on Payment to Provide Additional Medicare Reimbursement up to 50% of the Cost of DIFICID Prescribed in Inpatient Setting Webcast and Conference Call to be Held August 2 at 9:00 a.m. Eastern Time SAN DIEGO, August 2, 2012 — Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) tod
August 3, 2012	EX-10.6	OPTIMER PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Exhibit 10.6 OPTIMER PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Optimer Pharmaceuticals, Inc. (the ?Company?) hereby awards to Participant the number of restricted stock units specified and on the terms set forth below (the ?Award?). The Award is subject to all of the terms and conditions as set forth herein and in the Company?s 2012 Equity Incentive Plan
August 3, 2012	EX-10.3	10110 SORRENTO VALLEY ROAD, SUITE C, SAN DIEGO, CALIFORNIA 92121 TEL: 858-909-0736 FAX: 858-909-0737 101 HUDSON STREET, SUITE 3501, JERSEY CITY, NJ 07302 TEL: 201-333-8819 FAX: 201-333-8870 Exhibit 10.3 April 6, 2012 John Prunty c/o Optimer Pharmaceuticals, Inc. 5355 Mira Sorrento Place San Diego, CA 92121 Re: Separation from Optimer Pharmaceuticals, Inc. Dear John: This letter sets forth the terms and conditions of our agreement (the “Agreement”) regarding the termination of your employment with OPTIMER PHARMACEUTICALS, INC. (the “Company”). This Agreement shall be effective as of t
July 31, 2012	EX-99.1	Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results Exhibit 99.1 Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results Webcast and conference call today at 5:00 p.m. Eastern Time San Diego, CA– July 31, 2012 – Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company’s financial results for the quarter ended June 30, 2012. Second Quarter 2012 Financial Highlights: · DIFICID® second quarter gross sales of $18.0 million
July 31, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a12-1732518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2012 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33291 33-0830300 (State or other jurisdiction o
July 24, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2012 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33291 33-0830300 (State or other jurisdiction of incorporation) (Commis
June 11, 2012	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / FRED ALGER MANAGEMENT INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* OPTIMER PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68401H104 (CUSIP Number) May 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
June 5, 2012	EX-99.1	Optimer Pharmaceuticals Appoints Stephen Webster as Chief Financial Officer Exhibit 99.1 Optimer Pharmaceuticals Appoints Stephen Webster as Chief Financial Officer SAN DIEGO, June 5, 2012—Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the appointment of Stephen Webster as Chief Financial Officer. Mr. Webster will be responsible for directing Optimer’s financial strategy, accounting and investor relations functions. “Stephen has a broad background in the bio
June 5, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2012 OPTIMER PHARMACEUTICALS, INC.
June 5, 2012	EX-99.2	10110 SORRENTO VALLEY ROAD, SUITE C, SAN DIEGO, CALIFORNIA 92121 TEL: 858-909-0736 FAX: 858-909-0737 101 HUDSON STREET, SUITE 3501, JERSEY CITY, NJ 07302 TEL: 201-333-8819 FAX: 201-333-8870 Exhibit 99.2 May 30, 2012 Stephen Webster Dear Steve, It is with great pleasure that I offer you the position of Chief Financial Officer with Optimer Pharmaceuticals, Inc., (“Optimer” or the “Company”) performing such duties as are normally associated with this position and such duties as are assigned to you from time to time. You will report to Pedro Lichtinger, Chief Executive Officer. We at Opt
May 29, 2012	EX-99.4	OPTIMER PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Exhibit 99.4 OPTIMER PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Optimer Pharmaceuticals, Inc. (the “Company”) hereby awards to Participant the number of restricted stock units specified and on the terms set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2012 Equity Incentive Plan
May 29, 2012	S-8	- S-8 As filed with the Securities and Exchange Commission on May 29, 2012 Registration No.
May 29, 2012	EX-99.2	- EX-99.2 Exhibit 99.2 OPTIMER PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Optimer Pharmaceuticals, Inc. (the “Company”), pursuant to its 2012 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this
May 29, 2012	EX-99.3	- EX-99.3 Exhibit 99.3 OPTIMER PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Optimer Pharmaceuticals, Inc. (the “Company”) hereby awards to Participant the number of restricted stock units specified and on the terms set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2012 Equity Incentive Plan
May 10, 2012	EX-3.1	- EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OPTIMER PHARMACEUTICALS, INC. OPTIMER PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: The name of the Corporation is Optimer Pharmaceuticals, Inc. SECOND: The original Certificate of Incorporati
May 10, 2012	EX-10.6	[Signature Page Follows] Exhibit 10.6 January 31, 2012 Via Federal Express Emily Wang Supervisor 6F., No.306, Sec. 2, Bade Rd., Zhongshan Dist., Taipei City 104, Taiwan (R.O.C.) Re: OPT-822/821 Products Dear Emily, Optimer Pharmaceuticals, Inc. (“Optimer”) and Optimer Biotechnology, Inc. (“OBI”) are parties to an Intellectual Property Assignment and License Agreement effective as of October 30, 2009 (the “Agreement”). Thi
May 10, 2012	EX-10.4	COLLABORATION AND LICENSE AGREEMENT Exhibit 10.4 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 EXECUTION COPY COLLABORATION AND LICENSE AGREEMENT This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into on March 29, 2012 (the “Effective Date”) between OPTIMER PHARMACEUTICALS, INC., a company organize
May 10, 2012	EX-99.2	OPTIMER PHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 29, 2012 AMENDED BY THE BOARD OF DIRECTORS: MARCH 27, 2012 APPROVED BY THE STOCKHOLDERS: MAY 9, 2012 Exhibit 99.2 OPTIMER PHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 29, 2012 AMENDED BY THE BOARD OF DIRECTORS: MARCH 27, 2012 APPROVED BY THE STOCKHOLDERS: MAY 9, 2012 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Optimer Pharmaceuticals, Inc. 2006 Equity Incentive Plan (t
May 10, 2012	EX-99.1	Optimer Pharmaceuticals Reports First Quarter 2012 Financial Results 31% Net Sales Increase Puts Optimer on Track to Achieve First Year Sales Target Under Cubist Co-Promote Agreement Webcast and conference call today at 5:00 p.m. EDT Exhibit 99.1 Optimer Pharmaceuticals Reports First Quarter 2012 Financial Results 31% Net Sales Increase Puts Optimer on Track to Achieve First Year Sales Target Under Cubist Co-Promote Agreement Webcast and conference call today at 5:00 p.m. EDT SAN DIEGO, May 10, 2012—Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company’s financial results for the quarter ended March 31, 2011
May 10, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33291 OPT
May 10, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2012 OPTIMER PHARMACEUTICALS, INC.
May 10, 2012	EX-10.5	SUPPLY AGREEMENT Exhibit 10.5 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 EXECUTION COPY SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (the “Agreement”) is entered into on March 29, 2012 (the “Effective Date”) between Optimer Luxembourg 2 S.à r.l., a company organized under the laws of Luxembourg (“O
May 4, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2012 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33291 (Commission File
April 23, 2012	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2012 OPTIMER PHARMACEUTICALS, INC.
April 23, 2012	EX-99.1	COMPENSATION AGREEMENT Exhibit 99.1 EXECUTION VERSION COMPENSATION AGREEMENT This COMPENSATION AGREEMENT (this “Agreement”) is made and entered into as of April 20, 2012 (the “Effective Date”), by and between AFOS, LLC, a Delaware limited liability company (“AFOS”), and Optimer Pharmaceuticals, Inc., a Delaware corporation (“Optimer”) (each individually may be hereinafter referred to as a “Party” and collectively referr
April 23, 2012	424B5	286,260 Shares Common Stock Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No.
April 20, 2012	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 9, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2012 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33291 (Commission File N
April 9, 2012	EX-99.1	Optimer Pharmaceuticals Announces Personnel Changes —Reports Preliminary First Quarter 2012 Gross Revenues of Approximately $16.45 Million, 36% Increase in Growth Compared to Fourth Quarter 2011— Exhibit 99.1 Optimer Pharmaceuticals Announces Personnel Changes —Reports Preliminary First Quarter 2012 Gross Revenues of Approximately $16.45 Million, 36% Increase in Growth Compared to Fourth Quarter 2011— SAN DIEGO, April 9, 2012— Optimer Pharmaceuticals [NASDAQ: OPTR] (“the Company” or “Optimer”) today announced its Board of Directors has appointed Hank McKinnell as its new Chairman. Dr. McKi
April 9, 2012	PRE 14A	- PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 30, 2012	8-K	Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2012 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33291 (Commission File
March 8, 2012	EX-10.50	1 Exhibit 10.50 December 20, 2011 Tessie Che 700 West E Street, Unit 3402 San Diego, CA 92101 Dear Tessie: This letter sets forth the terms and conditions of the separation agreement (the ?Agreement?) that Optimer Pharmaceuticals, Inc. (the ?Company?) is offering to you to aid in your employment transition. 1. Termination of Employment. The Company and you have mutually agreed that you will cease em
March 8, 2012	EX-21.1	JURISDICTION OF INCORPORATION: Exhibit 21.1 Subsidiaries of Optimer Pharmaceuticals, Inc.: NAME: JURISDICTION OF INCORPORATION: Optimer Biotechnology, Inc. Taiwan Optimer Pharmaceuticals Canada, Inc. Canada
March 8, 2012	EX-10.51	LEASE AGREEMENT Exhibit 10.51 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 15th day of December, 2011, between ARE-SD REGION NO. 33, LLC, a Delaware limited liability company (“Landlord”), and OPTIMER PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). Building: 4755 Nexus Centre Drive, San Diego, California 92121 Premises: The Building containing 45,255 rentable square feet, as determin
March 8, 2012	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33291 Optimer Pharmaceuticals, Inc.
March 7, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2012 OPTIMER PHARMACEUTICALS, INC.
March 7, 2012	EX-99.1	Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results Optimer reports $145 million in revenues and net income of $7.8 million Exhibit 99.1 Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results Optimer reports $145 million in revenues and net income of $7.8 million SAN DIEGO— March 7, 2012 — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today financial results for the fourth quarter and fiscal year ended December 31, 2011, and provided an update on the DIFICID® (fidaxomicin) launch for the first t
March 6, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 a12-646818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2012 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33291 33-0830300 (State or other jurisdic
February 14, 2012	SC 13G	OPTR / Optimer Pharmaceuticals Inc / SECTORAL ASSET MANAGEMENT INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Original filing)* OPTIMER PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68401H104 (CUSIP Number) DECEMBER 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 14, 2012	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 s212126sc13ga1.htm AMENDMENT NO. 1 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G /A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Optimer Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68401H104 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of This Statement) Che
February 13, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2012 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33291 (Commission Fil
February 13, 2012	EX-99.2	OPTIMER PHARMACEUTICALS, INC. AMENDED AND RESTATED SEVERANCE BENEFIT PLAN Exhibit 99.2 OPTIMER PHARMACEUTICALS, INC. AMENDED AND RESTATED SEVERANCE BENEFIT PLAN Section 1. INTRODUCTION. The Optimer Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan (the “Plan”) was originally established effective May 5, 2010, and is hereby further amended and restated in its entirety effective February 7, 2012 (the “Effective Date”). The Plan also amends and restates in
February 13, 2012	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / PROQUEST INVESTMENTS II LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
February 13, 2012	EX-99.1	Optimer Pharmaceuticals, Inc. - EX-99.1 Exhibit 99.1 Optimer Pharmaceuticals, Inc. Incentive Compensation Plan Optimer’s success in achieving key milestones depends to a significant degree upon the continued contributions of our staff and the ability to attract and retain the most talented and dedicated employees possible. Our Incentive Compensation Plan ties a portion of overall compensation to key strategic financial and operational g
February 10, 2012	SC 13G	OPTR / Optimer Pharmaceuticals Inc / PRICE T ROWE ASSOCIATES INC /MD/ - OPTR AS OF 12/31/2011 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OPTIMER PHARMACEUTICALS (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68401H104 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sched
February 7, 2012	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* OPTIMER PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68401H104 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which t
January 23, 2012	S-8	- S-8 As filed with the Securities and Exchange Commission on January 23, 2012 Registration No.
January 12, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2012 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33291 33-0830300 (State or other jurisdiction of (Commission File Nu
January 10, 2012	SC 13G/A	OPTR / Optimer Pharmaceuticals Inc / FRED ALGER MANAGEMENT INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* OPTIMER PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68401H104 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
January 9, 2012	EX-99.1	Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) tablets Launch DIFICID Treatments Shipped by Wholesalers Grew Almost 87% in Fourth Quarter of 2011 Exhibit 99.1 Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) tablets Launch DIFICID Treatments Shipped by Wholesalers Grew Almost 87% in Fourth Quarter of 2011 San Diego, CA— January 9, 2012 — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today provided an update on commercial sales of DIFICID® (fidaxomicin) tablets since launching the antibacterial drug in July 2011 for the treat
January 9, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2012 OPTIMER PHARMACEUTICALS, INC.
December 19, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2011 OPTIMER PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2011 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33291 (Commission Fi
November 16, 2011	424B3	PROSPECTUS Common Stock Preferred Stock Debt Securities Warrants Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(3) Registration Statement No.
November 16, 2011	POS AM	As filed with the Securities and Exchange Commission on November 16, 2011 As filed with the Securities and Exchange Commission on November 16, 2011 Registration No.
November 3, 2011	EX-12.1	STATEMENT OF COMPUTATION ON RATIOS QuickLinks - Click here to rapidly navigate through this document Exhibit 12.1 STATEMENT OF COMPUTATION ON RATIOS The following table sets forth our ratio of earning to fixed chares and to combined fixed charges and preferred stock dividends for the years ended December 31, 2006, 2007, 2008, 2009, 2010 and six months ended June 30, 2011: Fixed Charges Year Ended December 31, Nine Months Ended Sept
November 3, 2011	EX-4.12	OPTIMER PHARMACEUTICALS, INC. , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF EXHIBIT 4.12 OPTIMER PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF OPTIMER PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between OPTIMER PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized a
November 3, 2011	EX-10.2	SECOND AMENDMENT Exhibit 10.2 SECOND AMENDMENT THIS SECOND AMENDMENT (this ?Amendment?) is made and entered into as of July 26, 2011, by and between TRIZEC SORRENTO TOWERS, LLC, a Delaware limited liability company (?Landlord?), and OPTIMER PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are parties to that certain lease dated August 18, 2008, as previously amended by Noti
November 3, 2011	EX-10.5	OPTIMER PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE Exhibit 10.5 OPTIMER PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE Optimer Pharmaceuticals, Inc. (the “Company”), hereby awards to the service provider set forth below the number of stock units set forth below in respect of shares of common stock of the Company’s subsidiary, Optimer Biotechnology, Inc., a Taiwanese corporation (“OBI”) (the “Award”). The Award is subject to all of the te
November 3, 2011	EX-4.10	OPTIMER PHARMACEUTICALS, INC. , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF EXHIBIT 4.10 OPTIMER PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF OPTIMER PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between OPTIMER PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and, a [corporation] [national banking association] organized and existin
November 3, 2011	EX-10.4	THIRD AMENDMENT TO LEASE Exhibit 10.4 THIRD AMENDMENT TO LEASE 1. PARTIES 1.1 THIS AGREEMENT made the 30th day of September, 2011 is between 101 HUDSON LEASING ASSOCIATES (?Landlord?) whose address is c/o Mack-Cali Realty Corporation, 343 Thornall Street, P.O. 7817, Edison, NJ 08818-7817 and OPTIMER PHARMACEUTICALS, INC. (?Tenant?), whose address is 10110 Sorrento Valley Road, Suite C, San Diego, California 92121. 2. STAT
November 3, 2011	EX-10.1	SECOND AMENDMENT TO LEASE Exhibit 10.1 SECOND AMENDMENT TO LEASE 1. PARTIES 1.1 THIS AGREEMENT made the 5th day of July, 2011 is by and between 101 HUDSON STREET ASSOCIATES (“Landlord”) whose address is c/o Mack-Cali Realty Corporation, 343 Thornall Street, P.O. Box 7817, Edison, New Jersey 08818-7817 and OPTIMER PHARMACEUTICALS, INC. (“Tenant”) whose address is 10110 Sorrento Valley Road, Suite C, San Diego, California 92
November 3, 2011	EX-99.1	Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results Optimer will host a webcast and conference call at 5:00 p.m. ET today Exhibit 99.1 Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results Optimer will host a webcast and conference call at 5:00 p.m. ET today SAN DIEGO ? November 3, 2011 ? Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company?s financial results for the quarter ended September 30, 2011. Optimer reported total revenues for the third quarter of 2011 of $11.1 million, co
November 3, 2011	EX-10.3	SECOND LEASE EXTENSION AND ADDENDUM Exhibit 10.3 SECOND LEASE EXTENSION AND ADDENDUM This Second Lease Extension and Addendum (“Second Extension”) is made and entered into the 26th day of July, 2011 by and between HELF Sorrento, LLC, a California Limited Liability Company (as “Landlord”) and Optimer Pharmaceuticals, Inc. a Delaware corporation (as “Tenant”), for those certain premises known as 10110 Sorrento Valley Rd., Suite C, San
November 3, 2011	EX-4.11	OPTIMER PHARMACEUTICALS, INC. , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF EXHIBIT 4.11 OPTIMER PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF OPTIMER PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between OPTIMER PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?) and , a [corporation] [national banking association] organized a
November 3, 2011	EX-4.7	OPTIMER PHARMACEUTICALS, INC. DATED AS OF [ ], 20 SUBORDINATED DEBT SECURITIES EXHIBIT 4.7 OPTIMER PHARMACEUTICALS, INC. AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF [ ], 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certif
November 3, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2011 OPTIMER PHARMACEUTICALS, INC.
November 3, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33291
November 3, 2011	S-3	As filed with the Securities and Exchange Commission on November 3, 2011 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on November 3, 2011 Registration No.
November 3, 2011	EX-4.6	OPTIMER PHARMACEUTICALS, INC. ISSUER [TRUSTEE], TRUSTEE DATED AS OF [ ], 20 SENIOR DEBT SECURITIES EXHIBIT 4.6 OPTIMER PHARMACEUTICALS, INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF [ ], 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions Of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation And Terms Of Securities 4 Section 2.02 Form Of Securities And Trustee’s Certi
October 11, 2011	SC 13G/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* OPTIMER PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68401H104 (CUSIP Number) September 30, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
September 30, 2011	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2011 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33291 33-0830300 (State or other jurisdiction of (Commission File
September 16, 2011	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 (Amendment No. )* Optimer SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 (Amendment No.
September 16, 2011	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Optimer Pharmaceuticals, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each
August 4, 2011	EX-10.2	CO-PROMOTION AGREEMENT by and between CUBIST PHARMACEUTICALS, INC. OPTIMER PHARMACEUTICALS, INC. Dated as of April 5, 2011 Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. Execution Copy CO-PROMOTION AGREEMENT by and between CUBIST PHARMACEUTICALS, INC. and OPTIMER PHARMACEUTICALS, INC. Dated as of April 5, 2011 TABLE OF CONTENTS 1. DEFINITIONS AND CONSTRUCTION 1 1.1 Definitions 1 1.2 Con
August 4, 2011	EX-10.5	Manufacturing Services Agreement June 1, 2011 Exhibit 10.5 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Standard Form Manufacturing Services Agreement June 1, 2011 Table of Contents ARTICLE 1 1 INTERPRETATION 1 1.1 DEFINITIONS 1 1.2 CURRENCY 5 1.3 SECTIONS AND HEADINGS 5 1.4 SINGULAR TERMS; INCLUDING 6 1.5 SCHEDULES 6 ARTI
August 4, 2011	EX-99.1	Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results Exhibit 99.1 Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results SAN DIEGO, CA - August 4, 2011 — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced its financial results for the quarter ended June 30, 2011. Optimer reported net loss for the second quarter of 2011 of $24.2 million, or ($0.52) per share on both a basic and diluted basis, as compared to a net loss for the
August 4, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2011 OPTIMER PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2011 OPTIMER PHARMACEUTICALS, INC.
August 4, 2011	EX-10.7	OPTIMER PHARMACEUTICALS, INC. 2006 EQUITY INCENTIVE PLAN NOTICE OF GRANT OF RESTRICTED STOCK UNITS Exhibit 10.7 OPTIMER PHARMACEUTICALS, INC. 2006 EQUITY INCENTIVE PLAN NOTICE OF GRANT OF RESTRICTED STOCK UNITS Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Notice of Grant. Name: [ ] You have been granted [ ] Restricted Stock Units. Each such Unit is equivalent to one Share of Common Stock of the Company for purposes of determining th
August 4, 2011	EX-10.1	AMENDMENT AGREEMENT to the Collaboration and License Agreement, dated February 2, 2011 and the Supply Agreement, dated February 2, 2011 Exhibit 10.1 AMENDMENT AGREEMENT to the Collaboration and License Agreement, dated February 2, 2011 and the Supply Agreement, dated February 2, 2011 by and between OPTIMER PHARMACEUTICALS, INC. 10110 Sorrento Valley Rd., Suite C San Diego, California 92121 (hereinafter referred to as “Optimer”), and ASTELLAS PHARMA EUROPE LTD. Lovett House, Lovett Road, Staines, Middlesex TW18 3AZ, United Kingdom
August 4, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33291 OPTI
August 4, 2011	EX-10.4	FIRST AMENDMENT TO LEASE Exhibit 10.4 FIRST AMENDMENT TO LEASE 1.0) PARTIES THIS AGREEMENT made the 4th day of May, 2011 is by and between 101 HUDSON LEASING ASSOCIATES (hereinafter “Landlord”) New Jersey general partnership, whose address is c/o Mack-Cali Realty Corporation, 343 Thornall Street, 8th Floor, Edison, New Jersey 08837-2206 and OPTIMER PHARMACEUTICALS, INC. (hereinafter “Tenant”), a Delaware corporation, whos
June 10, 2011	S-8	As filed with the Securities and Exchange Commission on June 10, 2011 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Optimer Pharmaceuticals, In As filed with the Securities and Exchange Commission on June 10, 2011 Registration No.
June 10, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2011 OPTIMER PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2011 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33291 33-0830300 (State or other jurisdiction of (Commission File Number
June 10, 2011	EX-99.1	OPTIMER PHARMACEUTICALS, INC. 2006 EQUITY INCENTIVE PLAN Exhibit 99.1 OPTIMER PHARMACEUTICALS, INC. 2006 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: · to attract and retain the best available personnel for positions of substantial responsibility, · to provide additional incentive to Employees, Directors and Consultants, and · to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock
June 3, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 1, 2011 OPTIMER PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 1, 2011 OPTIMER PHARMACEUTICALS, INC.
May 31, 2011	EX-99.1	FDA Approves Optimer?s DIFICID? (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD) ? In two CDAD clinical trials, DIFICID was non-inferior to vancomycin in clinical response at the end of therapy Exhibit 99.1 FDA Approves Optimer?s DIFICID? (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD) ? In two CDAD clinical trials, DIFICID was non-inferior to vancomycin in clinical response at the end of therapy and superior to vancomycin in sustained clinical response 25 days post-treatment ? Optimer to host conference call for investors on May
May 31, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2011 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33291 33-0830300 (State or other jurisdiction of incorporation) (Commiss
May 6, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33291 OPT
May 6, 2011	EX-10.2	COLLABORATION AND LICENSE AGREEMENT Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 EXECUTION COPY COLLABORATION AND LICENSE AGREEMENT This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of the 2nd day of February, 2011 (the “Effective Date”) between OPTIMER PHARMACEUTICALS, INC.,
May 6, 2011	EX-10.3	SUPPLY AGREEMENT Exhibit 10.3 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406. EXECUTION COPY SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (the “Agreement”) is entered into as of the 2nd day of February, 2011 (the “Effective Date”) between OPTIMER PHARMACEUTICALS, INC., a company organized under the laws
May 6, 2011	EX-99.1	Optimer Pharmaceuticals, Inc. Consolidated Statements of Operations Exhibit 99.1 Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results SAN DIEGO — May 5, 2011 - Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced its financial results for the quarter ended March 31, 2011. Optimer reported net income for the first quarter of 2011 of $45.1 million, or $1.06 and $1.04 per basic and diluted share, respectively, as compared to a net loss for the
May 6, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2011 OPTIMER PHARMACEUTICALS, INC.
April 29, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2011 OPTIMER PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2011 OPTIMER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33291 (Commission File
April 29, 2011	EX-99.1	Summary of Optimer Pharmaceuticals, Inc. 2011 Incentive Compensation Plan Exhibit 99.1 Summary of Optimer Pharmaceuticals, Inc. 2011 Incentive Compensation Plan Optimer Pharmaceuticals, Inc. (the “Company”) has adopted this 2011 Incentive Compensation Plan (the “Plan”) for its Chief Executive Officer, Senior Vice Presidents, Executive Officers, Vice Presidents, executive directors, senior directors, directors, associate directors, senior managers and senior research inv
April 12, 2011	S-8	As filed with the Securities and Exchange Commission on April 11, 2011 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Optimer Pharmaceuticals, I As filed with the Securities and Exchange Commission on April 11, 2011 Registration No.

OPTR / Optimer Pharmaceuticals Inc - SEC备案- 年度报告、委托书

基本统计

SEC Filings

SEC Filings (Chronological Order)